Biovest Conducts End of Phase III Review with FDA of BiovaxID? as ... 4-traders This includes rituximab which when used as a consolidation agent (rituximab maintenance) is generally administered on a bi-monthly dosing schedule over several years resulting in immunosuppression that is significantly prolonged as compared to the use ... |
